Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Le Lézard8m
VANTAGE FOUNDATION PARTNERS WITH SOS CHILDREN'S VILLAGES PHILIPPINES TO EMPOWER VULNERABLE CHILDREN AND FAMILIES
Vantage Foundation proudly announces its partnership with SOS Children's Villages Philippines, a NGO committed to providing ...
Le Lézard8m
Weekly Roundup: 15 Tech Press Releases You Need to See
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help tech journalists and consumers stay on top of the week's most newsworthy ...
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing ...
PharmiWeb19h
Alzheimer’s Therapeutics Market Set to Grow at a 9.2% CAGR, Reaching USD 7,359.7 Million by 2033
Alzheimer’s Therapeutics MarketThe global Alzheimer’s therapeutics market is projected to experience significant growth, with an expected valuation of USD 3,052.3 million in 2023. The market is ...
Allarity Therapeutics, Inc.: Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments ...
Metastatic Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight
DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...